Botox brow lift: what is really known about lifting the eyebrow
Slightly lifting the tail of the eyebrow with botulinum toxin is a practice described in the medical literature, but it is not in any French product label: it is an off-label use. The measured effect is small, around one millimetre. Here is how it works, what is known, and what to ask your doctor.
The eyebrows are one of the eleven areas of our atlas of botulinum toxin by area of the face. This page is about the brow lift: how it works, what studies show, why it is an off-label use in France, and what its risks are. It does not replace a consultation.
Why is this area treated?
The position of the eyebrow results from a balance between muscles that pull it up and muscles that pull it down. The frontalis lifts it. Other muscles lower it: those of the area between the eyebrows, used for frowning (see the page on frown lines and their muscles), and the outer part of the orbicularis oculi, the ring of muscle around the eye.
A botulinum toxin brow lift relies on this principle: by relaxing some of the muscles that pull the eyebrow down, the frontalis can act a little more, and the eyebrow may rise slightly. In the most often cited study, the toxin was injected into the area between the eyebrows and above the outer part of the eyebrow1.
This point is often misunderstood: you do not lift the eyebrow by treating the forehead. On the contrary, relaxing the frontalis can make the eyebrow drop, an effect described in the labels2. Horizontal lines have their own page, on injections for forehead lines.
What the toxin does not do: it does not replace eyebrow or eyelid surgery, and it does not correct excess skin.
When is the toxin used?
No French label defines an indication for this area, so there are no official criteria. The main published study on the subject, without a control group, shows a modest effect: among seven women aged 31 to 42, five had a lift of 1–3 mm (1 mm on average), two had no change, and all had less marked frowning1. This is a low level of evidence, in very few people.
The contraindications in the labels apply whatever the area: allergy to the toxin or to a component of the product, a generalised disorder of the muscles and of the junction between nerve and muscle (myasthenia gravis, Lambert-Eaton syndrome), an infection at the injection site2,3. Treatment is not recommended during pregnancy or breastfeeding2,3.
Which toxin for the eyebrows?
| Toxin | Status in France |
|---|---|
| Long-acting botulinum toxin (type A) | No aesthetic indication for this area in the SmPCs in force in France: off-label use, to be discussed with your doctor |
| Short-acting botulinum toxin (serotype E) | No aesthetic indication for this area in the SmPCs in force in France: off-label use, to be discussed with your doctor |
The type A toxins approved for aesthetic use in France cover frown lines and, depending on the product, crow’s feet and forehead lines2,4,5. None provides for a brow lift. The short-acting botulinum toxin (serotype E) is approved for frown lines only, in the European Union and in Canada3,6. For this area, any injection is therefore off-label, whatever the toxin.
Is it right for me?
Your doctor will examine the position and symmetry of your eyebrows, the appearance of your upper eyelids, and how your forehead and the area between your eyebrows move. A low eyebrow caused by excess skin or sagging tissue does not call for the same approach as an eyebrow pulled down by very active muscles.
Your expectations also need to be realistic: the measured effect is around one millimetre, and not everyone gets it1.
Questions to ask your doctor: is this use off-label, and why are you suggesting it? What result is reasonable in my case? What alternatives exist? What happens if one eyebrow rises more than the other?
Onset and duration
No label gives an onset or duration for this area. In the reference study, the result was measured one month after the injection1. For frown lines and the forehead, the labels of type A toxins describe an improvement within a few days and an effect shown for about 4 months2,4.
How these timelines work in general is explained on the page about how long botulinum toxin takes to work.
What are the risks in this area?
The effects most often described around the eyebrow are a drooping eyebrow, the Mephisto sign (tail of the eyebrow arched upwards) and a drooping upper eyelid2,3. They are temporary. The eyelid is a sensitive area, covered on the page about injections near the eyelids. Small bruises and headaches are also possible2.
Difficulty swallowing, speaking or breathing requires immediate medical attention2,3. A visual disturbance should also be checked by a doctor promptly. If the result worries you, the page on the eyebrows after an injection describes the most common situations, such as an eyebrow that is too high or drooping.
Key points
- The eyebrow rises when some of the muscles that pull it down are relaxed, not when the forehead is treated1,2.
- The measured effect is small: 1 mm on average, in seven people1.
- No French label provides for this use: it is off-label, for every toxin2,3.
- Main risks: a drooping or overly raised eyebrow, a drooping eyelid, all temporary2,3.
Frequently asked questions
Can botulinum toxin lift the eyebrows?
Slightly, in some people. In a small 1999 study of seven women, treating the muscles that pull the eyebrow down lifted it by 1–3 mm in five of them, with a mean of 1 mm; two had no change1. This is a modest effect, measured in very few people, and this use is not in any French product label.
Is a botulinum toxin brow lift approved in France?
Why can the eyebrow drop instead of rising?
Because the forehead muscle is the muscle that lifts the eyebrow. If it is relaxed, the eyebrow can drop: the label of a type A toxin describes eyebrow drooping as a common effect of forehead treatment2. This is why a brow lift targets other muscles, those that pull the eyebrow down1, and why eyebrow position is examined before any injection.
Sources
- 1.Huilgol S.C. et al., eyebrow lift with botulinum toxin, Dermatologic Surgery, 1999 (opens in a new tab) — Dermatologic Surgery
- 2.SmPC of a type A botulinum toxin approved for aesthetic use in France (BDPM, CIS 68150775) (opens in a new tab) — French public medicines database (BDPM)
- 3.Summary of product characteristics of the serotype E botulinum toxin approved in the European Union (EPAR annex I) (opens in a new tab) — European Commission (Union Register of medicinal products)
- 4.SmPC of a type A botulinum toxin approved for aesthetic use in France (BDPM, CIS 61592762) (opens in a new tab) — French public medicines database (BDPM)
- 5.SmPC of a type A botulinum toxin approved for aesthetic use in France (BDPM, CIS 66865211) (opens in a new tab) — French public medicines database (BDPM)
- 6.Canadian product monograph of the serotype E botulinum toxin (authorization date: 2026-06-22) (opens in a new tab) — Health Canada